American Bio Medica wins legal round in patent dispute
This article was originally published in Clinica
American Bio Medica has won the latest round in its patent litigation with Phamatech concerning urine-based drug-of-abuse testing kits in the US. The Delaware district court has denied Phamatech's request to throw out American Bio Medica's patent infringement case against Phamatech and other defendants. The trial has also been moved to California, the home state of Phamatech.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.